Catalyst Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Catalyst Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,000	Closed	-$306K	–	496
2016 Q2	$306K	Buy	+10,000	New	+$347K	0.06%	232
2015 Q2	–	Sell	-13,600	Closed	-$481K	–	522
2015 Q1	$481K	Buy	13,600 +6,098	+81%	+$218K	0.06%	208
2014 Q4	$256K	Buy	7,502 +2,197	+41%	+$78K	0.03%	292
2014 Q3	$205K	Buy	+5,305	New	+$198K	0.03%	281

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Catalyst Capital Advisors's MYGN Position: Q3 2016 in Review

Catalyst Capital Advisors sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 10,000 shares — an estimated $306K sold.

Catalyst Capital Advisors first reported a position in MYGN in Q3 2014 and held it in 4 quarters. The position peaked at $481K in Q1 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Catalyst Capital Advisors reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Catalyst Capital Advisors sold 10,000 Myriad Genetics shares in Q3 2016, an estimated $306K.
Catalyst Capital Advisors first reported a position in Myriad Genetics in Q3 2014 and held it in 4 quarters.
Catalyst Capital Advisors's Myriad Genetics position peaked at $481K in Q1 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Catalyst Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.